As adjuvant therapy for breast cancer has become more generally used, there seems to be a decreased need for prognostic factors. Nonetheless it remains a challenge to predict which patients are at ...
Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). Safety and efficacy of FOLFOXIRI with ...
A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer No significant financial relationships to disclose. This is an ASCO Meeting ...
Tumor M2 Pyruvate Kinase: A Tumor Marker and its Clinical Application in Gastrointestinal Malignancy
Expert Rev Mol Diagn. 2008;8(5):579-585. Quite a few tumor markers (CEA, CA 19-9, AFP, SCC, CA 72-4.) have already been established in diagnosis and/or surveillance of malignant diseases of the GI ...
“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to ...
A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, "Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management ...
This project is designed to further validate the efficiency of Onko-Sure® relative to the Carcinoembryonic Antigen (CEA) marker in colorectal cancer patients. Specifically, RPC's study compares the ...
Please provide your email address to receive an email when new articles are posted on . Elevated postoperative serum carcinoembryonic antigen increased risk for recurrence, especially within the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results